Drotrecogin alfa activated (Xigris)
Phase 2Completed 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease
Conditions
End Stage Renal Disease
Trial Timeline
Oct 1, 2008 → Dec 1, 2010
NCT ID
NCT01227187About Drotrecogin alfa activated (Xigris)
Drotrecogin alfa activated (Xigris) is a phase 2 stage product being developed by Eli Lilly for End Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01227187. Target conditions include End Stage Renal Disease.
What happened to similar drugs?
20 of 20 similar drugs in End Stage Renal Disease were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01227187 | Phase 2 | Completed |
Competing Products
20 competing products in End Stage Renal Disease